Missling, PhD, MS, MBA, president and CEO of Anavex Life Sciences, said that the result wasnt entirely surprising to many in the field, though it was disappointing given the initial optimism. Heres why Alzheimers disease is complex, said Missling
In the STEP-1 trial, people taking semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks
The first GLP-1 receptor agonist was approved for clinical use by the US Food and Drug Administration on April 28, 2005
Archived from the original on 6 January 2024
Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, Daler-Plenker J, Guerci P, Huynh C, Knight JS, Loda M, Looney MR, McAllister F, Rayes R, Renaud S, Rousseau S, Salvatore S, Schwartz RE, Spicer JD, Yost CC, Weber A, Zuo Y, Egeblad M (2020) Targeting potential drivers of COVID-19: neutrophil extracellular traps
The weight loss potential may be appealing to patients with Type 2 diabetes who are looking to lose weight as part of their overall diabetes management strategy